Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia
- 1 August 2002
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 30 (4) , 243-251
- https://doi.org/10.1038/sj.bmt.1703641
Abstract
Allogeneic stem cell transplantation (SCT) is one of the most expensive medical procedures. However, only a few studies to date have addressed the costs of HLA-identical sibling transplantation and only one study has reported costs of unrelated transplantation. No recent cost analysis with a proper follow-up period and donor identification expenses is available on related or voluntary matched unrelated donor (MUD) SCT for adult AML or ALL. Therefore, we calculated direct medical (hospital) costs based on 97 adults who underwent HLA-identical sibling bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT), and patients who received a graft from a MUD between 1994 and 1999. The average costs per transplanted patient were € 98 334 (BMT), €151 754 (MUD), and €98 977 (PBSCT), including donor identification expenses, 2 years follow-up and costs of patients who were not transplanted after they had been planned to receive an allograft. The majority of these costs was generated during the hospitalisation for graft infusion. For MUD transplants, nearly one-third of these costs was spent on the search for a suitable donor. For patients who were alive after 2 years, cumulative expenses were calculated to be €103 509 (BMT), €173 587 (MUD), and €105 906 (PBSCT).Keywords
This publication has 12 references indexed in Scilit:
- Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomised trialEuropean Journal Of Cancer, 2001
- Hematopoietic stem cell transplantation activity in Europe 1999Bone Marrow Transplantation, 2001
- Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know?Bone Marrow Transplantation, 1998
- Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin’s lymphoma patientsBone Marrow Transplantation, 1997
- Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1997
- Granulocyte‐macrophage colony‐stimulating factor as adjunct therapy in relapsed lymphoid malignancy: Implications for economic analyses of phase III clinical trialsThe International Journal of Cell Cloning, 1995
- Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (Filgrastim); a Less costly alternative to autologous bone marrow transplantationEuropean Journal Of Cancer, 1994
- The American Society of Clinical Oncology and American Society of Hematology Recommended Criteria for the Performance of Bone Marrow Transplantation.Journal of Clinical Oncology, 1990
- Cost Effectiveness of Bone Marrow Transplantation in Acute Nonlymphocytic LeukemiaNew England Journal of Medicine, 1989
- A comparison of bone marrow transplantation with maintenance chemotherapy for patients with acute nonlymphoblastic leukemia in first complete remissionAmerican Journal of Clinical Oncology, 1984